Myastad (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myastad, is an immunosuppressant presented as an oral formulation for oral use. It is employed to lower the risk of organ transplant rejection and to treat lupus nephritis by inhibiting lymphocyte proliferation in transplant recipients and patients with autoimmune kidney disease.

GNH USA supplies Myastad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Myastad, an antimetabolite immunosuppressant, is indicated for conditions where immune modulation is required.

Organ transplant rejection: reduces the likelihood of acute and chronic graft rejection in kidney, heart and liver transplant recipients. Lupus nephritis: improves renal function and slows disease progression in patients with systemic lupus erythematosus affecting the kidneys.

Myastad may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Vomiting: occasional episodes. - Abdominal pain: cramping or discomfort. - Headache: transient mild pain. - Upper respiratory infections: increased susceptibility.

Serious or Rare Side Effects: - Leukopenia or neutropenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count. - Severe infections: opportunistic or systemic infections. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy risk: potential increased incidence of certain cancers. - Progressive multifocal leukoencephalopathy (PML): rare but serious brain infection.

Before initiating Myastad, clinicians should consider several safety measures.

Monitor blood counts: regular CBC to detect leukopenia or anemia. Assess renal function: adjust dosing in impaired kidneys. Avoid use in pregnancy: safety category unknown; weigh risks vs benefits. Counsel on infection risk: advise patients to report signs of infection promptly. Adjust for hepatic impairment: consider dose reduction in liver disease. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Myastad can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce drug exposure. - Antacids containing aluminum or magnesium: decrease absorption of mycophenolic acid.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - ACE inhibitors or ARBs: potential for increased nephrotoxicity. - NSAIDs: may exacerbate renal impairment. - Non‑live vaccines: monitor immune response.